Litcius/Paper detail

Peri-tumor administration of controlled release anti-CTLA-4 synergizes with systemic anti-PD-1 to induce systemic antitumor immunity while sparing autoimmune toxicity

Airi Harui, Sandra M. McLachlan, Basil Rapoport, Thomas I. Zarembinski, Michael D. Roth

2020Cancer Immunology Immunotherapy14 citationsDOIOpen Access PDF

Topics & Concepts

MedicineSystemic administrationToxicityCTLA-4AntibodyImmunologyImmunotherapyCancer immunotherapyImmune systemCancer researchInternal medicineT cellBiologyIn vivoBiotechnologyCancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesCAR-T cell therapy research
Peri-tumor administration of controlled release anti-CTLA-4 synergizes with systemic anti-PD-1 to induce systemic antitumor immunity while sparing autoimmune toxicity | Litcius